Dapagliflozin: Uses, Dosage, Side Effects & Precautions

Dapagliflozin is an SGLT2 inhibitor, primarily used to treat type 2 diabetes by helping the body remove excess sugar through the urine. It has also been approved for heart failure and chronic kidney disease, making it a versatile medicine for managing several chronic conditions.

Dapagliflozin at a Glance

Indications for Dapagliflozin

Dapagliflozin is prescribed for:

• Type 2 diabetes: Helps lower blood sugar levels by reducing how much glucose the kidneys reabsorb into the blood, alongside diet and exercise.

• Heart failure: Used in adults with heart failure, with or without type 2 diabetes, according to the applicable indication and product information, to reduce the risk of cardiovascular death and heart failure hospitalization.

• Chronic kidney disease: Slows the progression of kidney disease and reduces the risk of kidney failure, cardiovascular death, and heart failure hospitalization in adults with CKD who are at risk of the disease getting worse, with or without diabetes.

Dapagliflozin is not a treatment for type 1 diabetes or for diabetic ketoacidosis.

How Dapagliflozin Works

Dapagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which normally reabsorbs sugar back into the bloodstream. By blocking this, the drug causes extra glucose to pass out of the body through the urine, which helps lower blood sugar levels.

For heart failure and kidney disease, dapagliflozin appears to reduce fluid buildup and ease strain on the heart and kidneys, though the exact mechanisms in these conditions are not as fully understood as its effect on blood sugar. Large clinical trials have shown clear benefits for these conditions.

Dosage and Administration

Dapagliflozin is typically taken once daily, by mouth, with or without food, at the same time each day. There is no single dose that applies to everyone; the right dose depends on the condition being treated, the specific product and its approved label, kidney function, and your doctor’s judgment.

• Type 2 diabetes (glycemic control): Depending on the specific product label, treatment may be started at a lower dose, such as 5 mg once daily, and increased to 10 mg once daily if additional blood sugar control is needed.

• Heart failure and chronic kidney disease: In current major product information, 10 mg once daily is generally the labeled dose for these indications.

Because dosing recommendations can differ between products and regulatory labels, do not assume the same dose applies across every use. Do not start, stop, or change your dose without your doctor’s advice.

Before starting dapagliflozin, your doctor will typically assess your kidney function, hydration/volume status, and other relevant medical conditions and medicines, and will correct any significant dehydration or volume depletion before treatment begins.

Dapagliflozin and Kidney Function

Dapagliflozin’s effect on kidney function depends on why it’s being used:

• For blood sugar control in type 2 diabetes: Its glucose-lowering effect becomes less effective as kidney function (eGFR) declines, and some product labels do not recommend starting it for this purpose below a certain eGFR threshold.

• For heart failure or chronic kidney disease: Dapagliflozin can still be used at lower eGFR ranges than for diabetes control alone, depending on the specific indication and product labeling, because its benefit in these conditions doesn’t rely solely on lowering blood sugar.

Your doctor will check your kidney function before starting treatment and periodically afterward, and will decide whether dapagliflozin is appropriate for you and at what dose, based on the reason for treatment and your current kidney function.

Common Side Effects of Dapagliflozin

Like all medications, dapagliflozin has some potential side effects, including:

• Genital yeast infections: Higher glucose levels in the urine can promote yeast overgrowth in the genital area. Urinary tract infections have also been reported with dapagliflozin, though they are not necessarily caused by the same mechanism; rarely, a UTI can become serious.

• Dehydration and low blood pressure: Dapagliflozin increases the amount of glucose and fluid lost in the urine, which can lead to volume depletion or low blood pressure. This risk is higher in older adults, people with reduced kidney function, people with low blood pressure, and those taking diuretics.

• Acute kidney injury: Sudden worsening of kidney function can occur, particularly when there is dehydration/volume depletion or other risk factors. Seek medical attention promptly for severe dehydration, markedly reduced urination, or feeling very unwell.

• Diabetic ketoacidosis (DKA): Rarely, dapagliflozin can cause DKA, including in people with type 2 diabetes, sometimes without very high blood sugar levels. Factors that can increase this risk include prolonged fasting, surgery, acute illness, reduced food or fluid intake, excessive alcohol use, and a sudden reduction or interruption of insulin. Seek urgent medical care for nausea, vomiting, abdominal pain, tiredness, or difficulty breathing.

• Fournier’s gangrene: A rare but serious and life-threatening infection of the tissue around the genitals and perineum has been reported with SGLT2 inhibitors, including dapagliflozin. Seek emergency care for severe pain, tenderness, redness, or swelling in the genital or perineal area, together with fever or feeling generally unwell.

Patients should be advised to report any unusual symptoms to their healthcare provider.

Stopping Dapagliflozin Before Surgery

Because of the ketoacidosis risk, dapagliflozin is generally withheld for at least 3 days before surgery or procedures involving prolonged fasting, when possible. It is generally restarted once you are clinically stable and have resumed eating and drinking normally, as advised by your treating clinician. Only stop or restart this medicine on your doctor’s instructions.

Contraindications

Dapagliflozin should not be used in patients with:

• A history of a serious hypersensitivity (allergic) reaction to dapagliflozin or any component of the specific product

Depending on the exact product and its approved labeling, dialysis-dependent kidney failure may also be a formal contraindication; check the specific product information for the formulation you have been prescribed.

Other situations call for caution or mean the medicine is “not recommended,” rather than being formal contraindications:

• Type 1 diabetes: Dapagliflozin is not approved for type 1 diabetes and increases the risk of diabetic ketoacidosis in these patients.

• Reduced kidney function: Whether and how dapagliflozin is used depends on the reason for treatment and how low kidney function is, as explained above; this is a clinical decision, not a blanket restriction.

• Use with insulin or medicines that increase insulin release (insulin secretagogues, such as sulfonylureas): These combinations can increase the risk of low blood sugar, and your doctor may need to adjust the dose of the other medicine.

Effect on Pregnancy, Breastfeeding, Liver, and Kidneys

• Pregnancy: Dapagliflozin is generally not recommended during the later stages of pregnancy, because of potential effects on the developing kidneys of the baby. There isn’t enough human data to be certain about its effects earlier in pregnancy. If you become pregnant while taking dapagliflozin, or think you might be, contact your doctor promptly for advice rather than stopping or changing your treatment on your own.
• Breastfeeding: Dapagliflozin is not recommended while breastfeeding, consistent with current product information, because of a potential risk to the kidney development of a nursing infant.
• Liver: In people with severe liver impairment, exposure to dapagliflozin can be higher, which may affect how the medicine is tolerated. Treatment decisions in this situation, including whether any dose adjustment is needed, should be made by the treating clinician based on the specific product labeling, rather than following a universal rule.
• Kidneys: See “Dapagliflozin and Kidney Function” above. Your kidney function is checked before starting treatment and periodically afterward.

Popular Brand Names: India and US

Dapagliflozin is marketed under the following brand names:

• India: Forxiga (dapagliflozin alone), Xigduo (dapagliflozin with metformin)

• US: Farxiga (dapagliflozin alone), Xigduo XR (dapagliflozin with extended-release metformin), Qtern (dapagliflozin with saxagliptin)

Combination products carry their own additional warnings and contraindications beyond those of dapagliflozin alone (for example, metformin-containing products carry a warning about a rare but serious condition called lactic acidosis). Always check which product and combination you have been prescribed, and refer to that product’s specific label, since dosing and contraindications can differ between products and regions.

How HealthPil Can Help

If you’re managing diabetes, heart failure, or kidney disease, you can consult a qualified doctor through HealthPil about your condition and questions about dapagliflozin and other treatment options. Medicines should be started, adjusted, or stopped only under the guidance of a qualified healthcare professional.